



Attorney Docket No.: 26230

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

DIETRICH, et al.

Serial No.: 10/505,138

Group Art: 1615

Filed: August 19, 2004

Examiner: SILVERMAN, E.

For: **ORAL DOSAGE FORM CONTAINING A PDE 4 INHIBITOR AS AN ACTIVE
INGREDIENT AND POLYVINYLPYRROLIDON AS EXCIPIENT**

REQUEST FOR

CONTINUED EXAMINATION (RCE)

TRANSMITTAL

Commissioner for Patents
Box RCE
P.O. Box 1450
Alexandria, VA 22313-1450

Application No.	10/505,138
Filing Date:	August 19, 2004
Title:	ORAL DOSAGE FORM CONTAINING A PDE 4 INHIBITOR AS AN ACTIVE INGREDIENT AND POLYVINYLPYRROLIDON AS EXCIPIENT
Inventor:	DIETRICH, et al.
Group Art Unit:	1615
Examiner:	SILVERMAN, E.
Atty Docket No.:	26230

Sir:

This is a Request for Continued Examination (RCE) under 37 C.F.R § 1.114 of the above-identified application.

Note: 37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, applicant may wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53(d) (PTO/SB/29) instead of a RCE to be eligible for the patent term adjustment provisions of the AIPA. See Changes to Application Examination and Provisional Application and Provisional Application Practice, Final Rule 65 Fed.Reg. 50092 9Aug. 16, 2000; Interim Rule, 65 Fed. Reg. 14865 (mar. 20, 2000), 1233 Off.Gaz. Pat. Office 47 (Apr. 11, 2000), which established RCE practice

08/30/2007 MAHHEE1 00000031 10505138
01 FC:1801

790.00 00

1.1. Submission required under 37 C.F.R. § 1.114

a. Previously submitted

1. Consider the amendments(s)/reply under 37 C.F.R. § 1.116 previously filed on .
- ii. Consider the arguments in the Appeal Brief or Reply Brief previously filed on .
2. Other .

2. X Enclosed

1. X Amendment
2. X Reply
3. Affidavit(s)/Declaration(s)
4. Information Disclosure Statement(IDS)
5. Other .

2. Miscellaneous

- a. Suspension of action on the above-identified application is requested under 37 C.F.R. § 1.103(c) for a period of months. (Period of suspension shall not exceed 3 months; Fee under 37 C.F.R. § 1.17(i) required)
- b. Other .

3. Fees

(The RCE fee under 37 C.F.R. § 1.17(e) is required by 37 C.F.R. § 1.114 when the RCE is filed)

1. X The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Act. No. 14-0112.
 - i. X RCE fee of \$790.00 required under 37 C.F.R. § 1.17 (e) is enclosed.
 - ii. Extension of time fee (37 C.F.R. §§ 1.136 and 1.17)
 - iii. Other .

Date: August 29, 2007

THE NATH LAW GROUP
112 South West Street
Alexandria, VA 22314

GMN:JBG:RCE2.doc

Respectfully submitted,
THE NATH LAW GROUP

Gary M. Nath
Gary M. Nath
Registration No. 26,965
Joshua B. Goldberg
Registration No. 44,126
Charles D. Niebyski
Registration No. 46,116
Customer No. 34375